According to the representative data of the Tumor Registry Munich, 38.1 % of prostate cancer patients received a primary androgen deprivation, whereas 20.5 % had an adjuvant hormonal treatment. Following surgical castration being the most common form of androgen deprivation, 5 alpha-dihydrotestosterone is still present in prostate cancer tissue. Therefore, a maximal androgen blockade (MAB) consisting of a chemical or surgical castration plus a pure or antigonadotropic antiandrogen, has been proposed. Indeed, MAB lowers the dihydrotestosterone-androgen-receptor complex and suppresses the growth-factor dominated signal transduction. This leads to a measurable increase of apoptosis. New is the finding that LHRH as well as LH (for example following surgical castration) are bound by receptors located at the prostate cancer cell. In 30 phase-III trials, MAB has been tested against monotherapy and a cancer-specific survival advantage of 3 to 6 months and a approximately 6-month delay of progression was demonstrated. The most effective form of MAB is the combination of a LHRH agonist - in contrast to surgical castration - with a well-tolerated pure antiandrogen. The quality of life during MAB is low, if a pure antiandrogen such as flutamide is used which leads to rather serious side-effects. At the present time, special indications for MAB are patients with minimal metastases, bone pain at the time of diagnosis, a neoadjuvant or adjuvant application in combination with a radical prostatectomy or radiotherapy and particularly intermittent androgen deprivation which is tested at the present time in at least 5 international studies. An endocrine withdrawal syndrome is observed in approximately 30 % of patients, if, following a PSA-relapse, the antiandrogen is discontinued. Little notice has been given to the use of prognosticators for the decision, whether a MAB is useful or not. Patients with good prognostic factors as defined by Sylvester have a clear advantage, if MAB is compared to monotherapy, whereas patients with a pure prognosis did not benefit. In addition to these prognostic factors up-front, the PSA dynamics under an initial MAB may be employed for the decision, if this form of androgen deprivation is to be continued or not. In essence, in contrast to a general use of MAB a more differential application based on quality-of-life issues and prognosis should be preferred.
| Urologe [B] 4•2001 386Das lokal fortgeschrittene und/oder metastasierte Prostatakarzinom ist in der Regel nicht heilbar. Es ist eine langsam progrediente und potentiell tödliche Erkrankung mit einer Zellverdopplungszeit von 3-4 Jahren im Anfangsstadium. Diese Fakten werden gegenwärtig oft verdrängt, wenn Patienten Rat in den Medien, in einer Onlinesprechstunde (beispielsweise http://www.prostata.de oder http://www.cpdr.org) oder von mehreren Spezialisten (multi opinion) suchen.Richtigerweise sollte den Patienten ein Spektrum von Therapiemodalitäten angeboten werden, die dem klassischen onkologischen Prinzip folgen: eingeschränkte Radikalität, aber erhaltene Funktion. Der Begriff der "Lebensqualität" sollte in den Mittelpunkt aller therapeutischer Bemühungen gerückt werden.Die systemische Therapie des lokal fortgeschrittenen oder metastasierten Prostatakarzinoms in Form einer endokrinen Manipulation und/oder Chemotherapie stellt somit heute sowohl quantitativ als auch qualitativ eine große Herausforderung für Patienten und Therapeuten dar.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.